<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
placeholder

Telisotuzumab Vedotin Yields Durable Responses in c-Met-Expressing NSCLC

Telisotuzumab vedotin shows promising activity in previously treated, c-Met-overexpressing, EGFR-wild-type nonsquamous non-small cell lung cancer (NSCLC), as presented by CU Cancer Center member David Ross Camidge, MD, PhD, at the ASCO Annual Meeting 2024. This phase 2 LUMINOSITY trial (NCT03539536) involved 161 patients with advanced or metastatic NSCLC and the overall response rate was 28.6%, with median progression-free survival of 5.7 months and median overall survival of 14.5 months.

Topics: Press Coverage

Comments

Related Stories